! The Capitol Complex is open to the public with some limitations. All meetings are still available virtually online. Please visit the Capitol Information page for details.

Download Zipped Introduced WordPerfect HB0023.ZIP
[Status][Bill Documents][Fiscal Note][Bills Directory]

H.B. 23

             1     

CONTROLLED SUBSTANCE MODIFICATIONS

             2     
2011 GENERAL SESSION

             3     
STATE OF UTAH

             4     
Chief Sponsor: Gage Froerer

             5     
Senate Sponsor: Allen M. Christensen

             6     
             7      LONG TITLE
             8      Committee Note:
             9          The Health and Human Services Interim Committee recommended this bill.
             10      General Description:
             11          This bill modifies provisions relating to the Utah Controlled Substances Act by creating
             12      a controlled class of listed synthetic cannabinoid substances found in products often
             13      referred to as "spice."
             14      Highlighted Provisions:
             15          This bill:
             16          .    expands the definition of a controlled substance to include a list of synthetic
             17      equivalent cannabinoid substances and their analogs and homologs found in
             18      products commonly referred to as "spice";
             19          .    clarifies that the tetrahydrocannabinols in Schedule I of the Utah Controlled
             20      Substances Act include those both naturally and synthetically derived;
             21          .    provides that it is an affirmative defense that the person produced, possessed, or
             22      administered any of these listed substances if the person:
             23              .    was engaged in medical research; and
             24              .    was a holder of a license to possess controlled substances for research;
             25          .    authorizes the Controlled Substances Advisory Committee to recommend
             26      placement of a substance on a controlled substance list if it finds that the substance
             27      has a potential for abuse and that an accepted standard has not been established for


             28      safe use in treatment for medical purposes;
             29          .    adds "spice" to the driver license provisions regarding driving under the influence;
             30      and
             31          .    provides that a legislative body of a political subdivision may not enact an
             32      ordinance that is less restrictive than any provision of the Utah Controlled
             33      Substances Act.
             34      Money Appropriated in this Bill:
             35          None
             36      Other Special Clauses:
             37          This bill provides an effective date.
             38      Utah Code Sections Affected:
             39      AMENDS:
             40          41-6a-517, as last amended by Laws of Utah 2009, Chapter 390
             41          58-37-2 (Superseded 07/01/11), as last amended by Laws of Utah 2010, Chapters 64
             42      and 101
             43          58-37-2 (Effective 07/01/11), as last amended by Laws of Utah 2010, Chapters 64, 101,
             44      and 276
             45          58-37-3, as last amended by Laws of Utah 1997, Chapter 64
             46          58-37-4, as last amended by Laws of Utah 2010, Chapter 106
             47          58-37-6, as last amended by Laws of Utah 2010, Chapter 287
             48          58-37-8, as last amended by Laws of Utah 2010, Chapter 64
             49          58-38a-203, as enacted by Laws of Utah 2010, Chapter 231
             50          58-38a-204, as enacted by Laws of Utah 2010, Chapter 231
             51      ENACTS:
             52          58-37-4.2, Utah Code Annotated 1953
             53     
             54      Be it enacted by the Legislature of the state of Utah:
             55          Section 1. Section 41-6a-517 is amended to read:
             56           41-6a-517. Definitions -- Driving with any measurable controlled substance in the
             57      body -- Penalties -- Arrest without warrant.
             58          (1) As used in this section:


             59          (a) "Controlled substance" [means any substance scheduled under Section 58-37-4 .]
             60      has the same meaning as in Section 58-37-2 .
             61          (b) "Practitioner" has the same meaning as [provided] in Section 58-37-2 .
             62          (c) "Prescribe" has the same meaning as [provided] in Section 58-37-2 .
             63          (d) "Prescription" has the same meaning as [provided] in Section 58-37-2 .
             64          (2) In cases not amounting to a violation of Section 41-6a-502 , a person may not
             65      operate or be in actual physical control of a motor vehicle within this state if the person has any
             66      measurable controlled substance or metabolite of a controlled substance in the person's body.
             67          (3) It is an affirmative defense to prosecution under this section that the controlled
             68      substance was:
             69          (a) involuntarily ingested by the accused;
             70          (b) prescribed by a practitioner for use by the accused; or
             71          (c) otherwise legally ingested.
             72          (4) (a) A person convicted of a violation of Subsection (2) is guilty of a class B
             73      misdemeanor.
             74          (b) A person who violates this section is subject to conviction and sentencing under
             75      both this section and any applicable offense under Section 58-37-8 .
             76          (5) A peace officer may, without a warrant, arrest a person for a violation of this
             77      section when the officer has probable cause to believe the violation has occurred, although not
             78      in the officer's presence, and if the officer has probable cause to believe that the violation was
             79      committed by the person.
             80          (6) The Driver License Division shall:
             81          (a) if the person is 21 years of age or older on the date of arrest:
             82          (i) suspend, for a period of 120 days, the driver license of a person convicted under
             83      Subsection (2) of an offense committed on or after July 1, 2009; or
             84          (ii) revoke, for a period of two years, the driver license of a person if:
             85          (A) the person has a prior conviction as defined under Subsection 41-6a-501 (2); and
             86          (B) the current violation under Subsection (2) is committed:
             87          (I) within a period of 10 years after the date of the prior violation; and
             88          (II) on or after July 1, 2009;
             89          (b) if the person is under 21 years of age on the date of arrest:


             90          (i) suspend, until the person is 21 years of age or for a period of 120 days, the driver
             91      license of a person convicted under Subsection (2) of an offense committed on or after July 1,
             92      2009; or
             93          (ii) revoke, until the person is 21 years of age or for a period of two years, the driver
             94      license of a person if:
             95          (A) the person has a prior conviction as defined under Subsection 41-6a-501 (2); and
             96          (B) the current violation under Subsection (2) is committed:
             97          (I) within a period of 10 years after the date of the prior violation; and
             98          (II) on or after July 1, 2009;
             99          (c) subtract from any suspension or revocation period the number of days for which a
             100      license was previously suspended under Section 53-3-223 or 53-3-231 , if the previous
             101      suspension was based on the same occurrence upon which the record of conviction is based;
             102      and
             103          (d) deny, suspend, or revoke a person's license for the denial and suspension periods in
             104      effect prior to July 1, 2009, for a conviction of a violation under Subsection (2) that was
             105      committed prior to July 1, 2009.
             106          (7) (a) The court shall notify the Driver License Division if a person fails to:
             107          (i) complete all court ordered screening and assessment, educational series, and
             108      substance abuse treatment; or
             109          (ii) pay all fines and fees, including fees for restitution and treatment costs.
             110          (b) Upon receiving the notification, the division shall suspend the person's driving
             111      privilege in accordance with Subsections 53-3-221 (2) and (3).
             112          (8) The court shall order supervised probation in accordance with Section 41-6a-507
             113      for a person convicted under Subsection (2).
             114          Section 2. Section 58-37-2 (Superseded 07/01/11) is amended to read:
             115           58-37-2 (Superseded 07/01/11). Definitions.
             116          (1) As used in this chapter:
             117          (a) "Administer" means the direct application of a controlled substance, whether by
             118      injection, inhalation, ingestion, or any other means, to the body of a patient or research subject
             119      by:
             120          (i) a practitioner or, in the practitioner's presence, by the practitioner's authorized agent;


             121      or
             122          (ii) the patient or research subject at the direction and in the presence of the
             123      practitioner.
             124          (b) "Agent" means an authorized person who acts on behalf of or at the direction of a
             125      manufacturer, distributor, or practitioner but does not include a motor carrier, public
             126      warehouseman, or employee of any of them.
             127          (c) "Consumption" means ingesting or having any measurable amount of a controlled
             128      substance in a person's body, but this Subsection (1)(c) does not include the metabolite of a
             129      controlled substance.
             130          (d) "Continuing criminal enterprise" means any individual, sole proprietorship,
             131      partnership, corporation, business trust, association, or other legal entity, and any union or
             132      groups of individuals associated in fact although not a legal entity, and includes illicit as well
             133      as licit entities created or maintained for the purpose of engaging in conduct which constitutes
             134      the commission of episodes of activity made unlawful by Title 58, Chapter 37, Utah Controlled
             135      Substances Act, Chapter 37a, Utah Drug Paraphernalia Act, Chapter 37b, Imitation Controlled
             136      Substances Act, Chapter 37c, Utah Controlled Substance Precursor Act, or Chapter 37d,
             137      Clandestine Drug Lab Act, which episodes are not isolated, but have the same or similar
             138      purposes, results, participants, victims, methods of commission, or otherwise are interrelated
             139      by distinguishing characteristics. Taken together, the episodes shall demonstrate continuing
             140      unlawful conduct and be related either to each other or to the enterprise.
             141          (e) "Control" means to add, remove, or change the placement of a drug, substance, or
             142      immediate precursor under Section 58-37-3 .
             143          (f) (i) "Controlled substance" means a drug or substance:
             144          (A) included in Schedules I, II, III, IV, or V of Section 58-37-4 ;
             145          (B) included in Schedules I, II, III, IV, or V of the federal Controlled Substances Act,
             146      Title II, P.L. 91-513; [or]
             147          (C) that is a controlled substance analog[.]; or
             148          (D) a substance listed in Section 58-37-4.2 .
             149          (ii) "Controlled substance" does not include:
             150          (A) distilled spirits, wine, or malt beverages, as those terms are defined in Title 32A,
             151      Alcoholic Beverage Control Act;


             152          (B) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or
             153      prevention of disease in human or other animals, which contains ephedrine, pseudoephedrine,
             154      norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold,
             155      transferred, or furnished as an over-the-counter medication without prescription; or
             156          (C) dietary supplements, vitamins, minerals, herbs, or other similar substances
             157      including concentrates or extracts, which:
             158          (I) are not otherwise regulated by law; and
             159          (II) may contain naturally occurring amounts of chemical or substances listed in this
             160      chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking
             161      Act.
             162          (g) (i) "Controlled substance analog" means a substance the chemical structure of
             163      which is substantially similar to the chemical structure of a controlled substance listed in
             164      Schedules I and II of Section 58-37-4 , or in Schedules I and II of the federal Controlled
             165      Substances Act, Title II, P.L. 91-513, or listed in Section 58-37-4.2 :
             166          (A) which has a stimulant, depressant, or hallucinogenic effect on the central nervous
             167      system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central
             168      nervous system of controlled substances in the schedules set forth in Subsection (1)(f), or a
             169      substance listed in Section 58-37-4.2 ; or
             170          (B) which, with respect to a particular individual, is represented or intended to have a
             171      stimulant, depressant, or hallucinogenic effect on the central nervous system substantially
             172      similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of
             173      controlled substances in the schedules or list set forth in this Subsection (1).
             174          (ii) "Controlled substance analog" does not include:
             175          (A) a controlled substance currently scheduled in Schedules I through V of Section
             176      58-37-4 or listed in Section 58-37-4.2 ;
             177          (B) a substance for which there is an approved new drug application;
             178          (C) a substance with respect to which an exemption is in effect for investigational use
             179      by a particular person under Section 505 of the Food, Drug, and Cosmetic Act, 21 U.S.C. 355,
             180      to the extent the conduct with respect to the substance is permitted by the exemption;
             181          (D) any substance to the extent not intended for human consumption before an
             182      exemption takes effect with respect to the substance;


             183          (E) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or
             184      prevention of disease in man or other animals, which contains ephedrine, pseudoephedrine,
             185      norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold,
             186      transferred, or furnished as an over-the-counter medication without prescription; or
             187          (F) dietary supplements, vitamins, minerals, herbs, or other similar substances
             188      including concentrates or extracts, which are not otherwise regulated by law, which may
             189      contain naturally occurring amounts of chemical or substances listed in this chapter, or in rules
             190      adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
             191          (h) "Conviction" means a determination of guilt by verdict, whether jury or bench, or
             192      plea, whether guilty or no contest, for any offense proscribed by Title 58, Chapters 37, 37a,
             193      37b, 37c, or 37d, or for any offense under the laws of the United States and any other state
             194      which, if committed in this state, would be an offense under Title 58, Chapters 37, 37a, 37b,
             195      37c, or 37d.
             196          (i) "Counterfeit substance" means:
             197          (i) any controlled substance or container or labeling of any controlled substance that:
             198          (A) without authorization bears the trademark, trade name, or other identifying mark,
             199      imprint, number, device, or any likeness of them, of a manufacturer, distributor, or dispenser
             200      other than the person or persons who in fact manufactured, distributed, or dispensed the
             201      substance which falsely purports to be a controlled substance distributed by any other
             202      manufacturer, distributor, or dispenser; and
             203          (B) a reasonable person would believe to be a controlled substance distributed by an
             204      authorized manufacturer, distributor, or dispenser based on the appearance of the substance as
             205      described under Subsection (1)(i)(i)(A) or the appearance of the container of that controlled
             206      substance; or
             207          (ii) any substance other than under Subsection (1)(i)(i) that:
             208          (A) is falsely represented to be any legally or illegally manufactured controlled
             209      substance; and
             210          (B) a reasonable person would believe to be a legal or illegal controlled substance.
             211          (j) "Deliver" or "delivery" means the actual, constructive, or attempted transfer of a
             212      controlled substance or a listed chemical, whether or not an agency relationship exists.
             213          (k) "Department" means the Department of Commerce.


             214          (l) "Depressant or stimulant substance" means:
             215          (i) a drug which contains any quantity of barbituric acid or any of the salts of barbituric
             216      acid;
             217          (ii) a drug which contains any quantity of:
             218          (A) amphetamine or any of its optical isomers;
             219          (B) any salt of amphetamine or any salt of an optical isomer of amphetamine; or
             220          (C) any substance which the Secretary of Health and Human Services or the Attorney
             221      General of the United States after investigation has found and by regulation designated
             222      habit-forming because of its stimulant effect on the central nervous system;
             223          (iii) lysergic acid diethylamide; or
             224          (iv) any drug which contains any quantity of a substance which the Secretary of Health
             225      and Human Services or the Attorney General of the United States after investigation has found
             226      to have, and by regulation designated as having, a potential for abuse because of its depressant
             227      or stimulant effect on the central nervous system or its hallucinogenic effect.
             228          (m) "Dispense" means the delivery of a controlled substance by a pharmacist to an
             229      ultimate user pursuant to the lawful order or prescription of a practitioner, and includes
             230      distributing to, leaving with, giving away, or disposing of that substance as well as the
             231      packaging, labeling, or compounding necessary to prepare the substance for delivery.
             232          (n) "Dispenser" means a pharmacist who dispenses a controlled substance.
             233          (o) "Distribute" means to deliver other than by administering or dispensing a controlled
             234      substance or a listed chemical.
             235          (p) "Distributor" means a person who distributes controlled substances.
             236          (q) "Division" means the Division of Occupational and Professional Licensing created
             237      in Section 58-1-103 .
             238          (r) (i) "Drug" means:
             239          (A) a substance recognized in the official United States Pharmacopoeia, Official
             240      Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any
             241      supplement to any of them, intended for use in the diagnosis, cure, mitigation, treatment, or
             242      prevention of disease in humans or animals;
             243          (B) a substance that is required by any applicable federal or state law or rule to be
             244      dispensed by prescription only or is restricted to administration by practitioners only;


             245          (C) a substance other than food intended to affect the structure or any function of the
             246      body of humans or other animals; and
             247          (D) substances intended for use as a component of any substance specified in
             248      Subsections (1)(r)(i)(A), (B), and (C)[, and (D)].
             249          (ii) "Drug" does not include dietary supplements.
             250          (s) "Drug dependent person" means any individual who unlawfully and habitually uses
             251      any controlled substance to endanger the public morals, health, safety, or welfare, or who is so
             252      dependent upon the use of controlled substances as to have lost the power of self-control with
             253      reference to the individual's dependency.
             254          (t) "Food" means:
             255          (i) any nutrient or substance of plant, mineral, or animal origin other than a drug as
             256      specified in this chapter, and normally ingested by human beings; and
             257          (ii) foods for special dietary uses as exist by reason of a physical, physiological,
             258      pathological, or other condition including but not limited to the conditions of disease,
             259      convalescence, pregnancy, lactation, allergy, hypersensitivity to food, underweight, and
             260      overweight; uses for supplying a particular dietary need which exist by reason of age including
             261      but not limited to the ages of infancy and childbirth, and also uses for supplementing and for
             262      fortifying the ordinary or unusual diet with any vitamin, mineral, or other dietary property for
             263      use of a food. Any particular use of a food is a special dietary use regardless of the nutritional
             264      purposes.
             265          (u) "Immediate precursor" means a substance which the Attorney General of the United
             266      States has found to be, and by regulation designated as being, the principal compound used or
             267      produced primarily for use in the manufacture of a controlled substance, or which is an
             268      immediate chemical intermediary used or likely to be used in the manufacture of a controlled
             269      substance, the control of which is necessary to prevent, curtail, or limit the manufacture of the
             270      controlled substance.
             271          (v) "Indian" means a member of an Indian tribe.
             272          (w) "Indian religion" means any religion:
             273          (i) the origin and interpretation of which is from within a traditional Indian culture or
             274      community; and
             275          (ii) which is practiced by Indians.


             276          (x) "Indian tribe" means any tribe, band, nation, pueblo, or other organized group or
             277      community of Indians, including any Alaska Native village, which is legally recognized as
             278      eligible for and is consistent with the special programs, services, and entitlements provided by
             279      the United States to Indians because of their status as Indians.
             280          (y) "Manufacture" means the production, preparation, propagation, compounding, or
             281      processing of a controlled substance, either directly or indirectly by extraction from substances
             282      of natural origin, or independently by means of chemical synthesis or by a combination of
             283      extraction and chemical synthesis.
             284          (z) "Manufacturer" includes any person who packages, repackages, or labels any
             285      container of any controlled substance, except pharmacists who dispense or compound
             286      prescription orders for delivery to the ultimate consumer.
             287          (aa) "Marijuana" means all species of the genus cannabis and all parts of the genus,
             288      whether growing or not; the seeds of it; the resin extracted from any part of the plant; and every
             289      compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds, or
             290      resin. The term does not include the mature stalks of the plant, fiber produced from the stalks,
             291      oil or cake made from the seeds of the plant, any other compound, manufacture, salt,
             292      derivative, mixture, or preparation of the mature stalks, except the resin extracted from them,
             293      fiber, oil or cake, or the sterilized seed of the plant which is incapable of germination. Any
             294      synthetic equivalents of the substances contained in the plant cannabis sativa or any other
             295      species of the genus cannabis which are chemically indistinguishable and pharmacologically
             296      active are also included.
             297          (bb) "Money" means officially issued coin and currency of the United States or any
             298      foreign country.
             299          (cc) "Narcotic drug" means any of the following, whether produced directly or
             300      indirectly by extraction from substances of vegetable origin, or independently by means of
             301      chemical synthesis, or by a combination of extraction and chemical synthesis:
             302          (i) opium, coca leaves, and opiates;
             303          (ii) a compound, manufacture, salt, derivative, or preparation of opium, coca leaves, or
             304      opiates;
             305          (iii) opium poppy and poppy straw; or
             306          (iv) a substance, and any compound, manufacture, salt, derivative, or preparation of the


             307      substance, which is chemically identical with any of the substances referred to in Subsection
             308      (1)(cc)(i), (ii), or (iii), except narcotic drug does not include decocainized coca leaves or
             309      extracts of coca leaves which do not contain cocaine or ecgonine.
             310          (dd) "Negotiable instrument" means documents, containing an unconditional promise
             311      to pay a sum of money, which are legally transferable to another party by endorsement or
             312      delivery.
             313          (ee) "Opiate" means any drug or other substance having an addiction-forming or
             314      addiction-sustaining liability similar to morphine or being capable of conversion into a drug
             315      having addiction-forming or addiction-sustaining liability.
             316          (ff) "Opium poppy" means the plant of the species papaver somniferum L., except the
             317      seeds of the plant.
             318          (gg) "Person" means any corporation, association, partnership, trust, other institution or
             319      entity or one or more individuals.
             320          (hh) "Poppy straw" means all parts, except the seeds, of the opium poppy, after
             321      mowing.
             322          (ii) "Possession" or "use" means the joint or individual ownership, control, occupancy,
             323      holding, retaining, belonging, maintaining, or the application, inhalation, swallowing, injection,
             324      or consumption, as distinguished from distribution, of controlled substances and includes
             325      individual, joint, or group possession or use of controlled substances. For a person to be a
             326      possessor or user of a controlled substance, it is not required that the person be shown to have
             327      individually possessed, used, or controlled the substance, but it is sufficient if it is shown that
             328      the person jointly participated with one or more persons in the use, possession, or control of
             329      any substances with knowledge that the activity was occurring, or the controlled substance is
             330      found in a place or under circumstances indicating that the person had the ability and the intent
             331      to exercise dominion and control over it.
             332          (jj) "Practitioner" means a physician, dentist, naturopathic physician, veterinarian,
             333      pharmacist, scientific investigator, pharmacy, hospital, or other person licensed, registered, or
             334      otherwise permitted to distribute, dispense, conduct research with respect to, administer, or use
             335      in teaching or chemical analysis a controlled substance in the course of professional practice or
             336      research in this state.
             337          (kk) "Prescribe" means to issue a prescription:


             338          (i) orally or in writing; or
             339          (ii) by telephone, facsimile transmission, computer, or other electronic means of
             340      communication as defined by division rule.
             341          (ll) "Prescription" means an order issued:
             342          (i) by a licensed practitioner, in the course of that practitioner's professional practice or
             343      by collaborative pharmacy practice agreement; and
             344          (ii) for a controlled substance or other prescription drug or device for use by a patient
             345      or an animal.
             346          (mm) "Production" means the manufacture, planting, cultivation, growing, or
             347      harvesting of a controlled substance.
             348          (nn) "Securities" means any stocks, bonds, notes, or other evidences of debt or of
             349      property.
             350          (oo) "State" means the state of Utah.
             351          (pp) "Ultimate user" means any person who lawfully possesses a controlled substance
             352      for the person's own use, for the use of a member of the person's household, or for
             353      administration to an animal owned by the person or a member of the person's household.
             354          (2) If a term used in this chapter is not defined, the definition and terms of Title 76,
             355      Utah Criminal Code, shall apply.
             356          Section 3. Section 58-37-2 (Effective 07/01/11) is amended to read:
             357           58-37-2 (Effective 07/01/11). Definitions.
             358          (1) As used in this chapter:
             359          (a) "Administer" means the direct application of a controlled substance, whether by
             360      injection, inhalation, ingestion, or any other means, to the body of a patient or research subject
             361      by:
             362          (i) a practitioner or, in the practitioner's presence, by the practitioner's authorized agent;
             363      or
             364          (ii) the patient or research subject at the direction and in the presence of the
             365      practitioner.
             366          (b) "Agent" means an authorized person who acts on behalf of or at the direction of a
             367      manufacturer, distributor, or practitioner but does not include a motor carrier, public
             368      warehouseman, or employee of any of them.


             369          (c) "Consumption" means ingesting or having any measurable amount of a controlled
             370      substance in a person's body, but this Subsection (1)(c) does not include the metabolite of a
             371      controlled substance.
             372          (d) "Continuing criminal enterprise" means any individual, sole proprietorship,
             373      partnership, corporation, business trust, association, or other legal entity, and any union or
             374      groups of individuals associated in fact although not a legal entity, and includes illicit as well
             375      as licit entities created or maintained for the purpose of engaging in conduct which constitutes
             376      the commission of episodes of activity made unlawful by Title 58, Chapter 37, Utah Controlled
             377      Substances Act, Chapter 37a, Utah Drug Paraphernalia Act, Chapter 37b, Imitation Controlled
             378      Substances Act, Chapter 37c, Utah Controlled Substance Precursor Act, or Chapter 37d,
             379      Clandestine Drug Lab Act, which episodes are not isolated, but have the same or similar
             380      purposes, results, participants, victims, methods of commission, or otherwise are interrelated
             381      by distinguishing characteristics. Taken together, the episodes shall demonstrate continuing
             382      unlawful conduct and be related either to each other or to the enterprise.
             383          (e) "Control" means to add, remove, or change the placement of a drug, substance, or
             384      immediate precursor under Section 58-37-3 .
             385          (f) (i) "Controlled substance" means a drug or substance:
             386          (A) included in Schedules I, II, III, IV, or V of Section 58-37-4 ;
             387          (B) included in Schedules I, II, III, IV, or V of the federal Controlled Substances Act,
             388      Title II, P.L. 91-513; [or]
             389          (C) [that is] a controlled substance analog[.]; or
             390          (D) a substance listed in Section 58-37-4.2 .
             391          (ii) "Controlled substance" does not include:
             392          (A) distilled spirits, wine, or malt beverages, as those terms are defined in Title 32B,
             393      Alcoholic Beverage Control Act;
             394          (B) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or
             395      prevention of disease in human or other animals, which contains ephedrine, pseudoephedrine,
             396      norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold,
             397      transferred, or furnished as an over-the-counter medication without prescription; or
             398          (C) dietary supplements, vitamins, minerals, herbs, or other similar substances
             399      including concentrates or extracts, which:


             400          (I) are not otherwise regulated by law; and
             401          (II) may contain naturally occurring amounts of chemical or substances listed in this
             402      chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking
             403      Act.
             404          (g) (i) "Controlled substance analog" means a substance the chemical structure of
             405      which is substantially similar to the chemical structure of a controlled substance listed in
             406      Schedules I and II of Section 58-37-4 , a substance listed in Section 58-37-4.2 , or in Schedules
             407      I and II of the federal Controlled Substances Act, Title II, P.L. 91-513:
             408          (A) which has a stimulant, depressant, or hallucinogenic effect on the central nervous
             409      system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central
             410      nervous system of controlled substances in the schedules set forth in Subsection (1)(f), a
             411      substance listed in Section 58-37-4.2 ; or
             412          (B) which, with respect to a particular individual, is represented or intended to have a
             413      stimulant, depressant, or hallucinogenic effect on the central nervous system substantially
             414      similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of
             415      controlled substances in the schedules or list set forth in this Subsection (1).
             416          (ii) "Controlled substance analog" does not include:
             417          (A) a controlled substance currently scheduled in Schedules I through V of Section
             418      58-37-4 ;
             419          (B) a substance for which there is an approved new drug application;
             420          (C) a substance with respect to which an exemption is in effect for investigational use
             421      by a particular person under Section 505 of the Food, Drug, and Cosmetic Act, 21 U.S.C. 355,
             422      to the extent the conduct with respect to the substance is permitted by the exemption;
             423          (D) any substance to the extent not intended for human consumption before an
             424      exemption takes effect with respect to the substance;
             425          (E) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or
             426      prevention of disease in man or other animals, which contains ephedrine, pseudoephedrine,
             427      norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold,
             428      transferred, or furnished as an over-the-counter medication without prescription; or
             429          (F) dietary supplements, vitamins, minerals, herbs, or other similar substances
             430      including concentrates or extracts, which are not otherwise regulated by law, which may


             431      contain naturally occurring amounts of chemical or substances listed in this chapter, or in rules
             432      adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
             433          (h) "Conviction" means a determination of guilt by verdict, whether jury or bench, or
             434      plea, whether guilty or no contest, for any offense proscribed by Title 58, Chapters 37, 37a,
             435      37b, 37c, or 37d, or for any offense under the laws of the United States and any other state
             436      which, if committed in this state, would be an offense under Title 58, Chapters 37, 37a, 37b,
             437      37c, or 37d.
             438          (i) "Counterfeit substance" means:
             439          (i) any controlled substance or container or labeling of any controlled substance that:
             440          (A) without authorization bears the trademark, trade name, or other identifying mark,
             441      imprint, number, device, or any likeness of them, of a manufacturer, distributor, or dispenser
             442      other than the person or persons who in fact manufactured, distributed, or dispensed the
             443      substance which falsely purports to be a controlled substance distributed by any other
             444      manufacturer, distributor, or dispenser; and
             445          (B) a reasonable person would believe to be a controlled substance distributed by an
             446      authorized manufacturer, distributor, or dispenser based on the appearance of the substance as
             447      described under Subsection (1)(i)(i)(A) or the appearance of the container of that controlled
             448      substance; or
             449          (ii) any substance other than under Subsection (1)(i)(i) that:
             450          (A) is falsely represented to be any legally or illegally manufactured controlled
             451      substance; and
             452          (B) a reasonable person would believe to be a legal or illegal controlled substance.
             453          (j) "Deliver" or "delivery" means the actual, constructive, or attempted transfer of a
             454      controlled substance or a listed chemical, whether or not an agency relationship exists.
             455          (k) "Department" means the Department of Commerce.
             456          (l) "Depressant or stimulant substance" means:
             457          (i) a drug which contains any quantity of barbituric acid or any of the salts of barbituric
             458      acid;
             459          (ii) a drug which contains any quantity of:
             460          (A) amphetamine or any of its optical isomers;
             461          (B) any salt of amphetamine or any salt of an optical isomer of amphetamine; or


             462          (C) any substance which the Secretary of Health and Human Services or the Attorney
             463      General of the United States after investigation has found and by regulation designated
             464      habit-forming because of its stimulant effect on the central nervous system;
             465          (iii) lysergic acid diethylamide; or
             466          (iv) any drug which contains any quantity of a substance which the Secretary of Health
             467      and Human Services or the Attorney General of the United States after investigation has found
             468      to have, and by regulation designated as having, a potential for abuse because of its depressant
             469      or stimulant effect on the central nervous system or its hallucinogenic effect.
             470          (m) "Dispense" means the delivery of a controlled substance by a pharmacist to an
             471      ultimate user pursuant to the lawful order or prescription of a practitioner, and includes
             472      distributing to, leaving with, giving away, or disposing of that substance as well as the
             473      packaging, labeling, or compounding necessary to prepare the substance for delivery.
             474          (n) "Dispenser" means a pharmacist who dispenses a controlled substance.
             475          (o) "Distribute" means to deliver other than by administering or dispensing a controlled
             476      substance or a listed chemical.
             477          (p) "Distributor" means a person who distributes controlled substances.
             478          (q) "Division" means the Division of Occupational and Professional Licensing created
             479      in Section 58-1-103 .
             480          (r) (i) "Drug" means:
             481          (A) a substance recognized in the official United States Pharmacopoeia, Official
             482      Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any
             483      supplement to any of them, intended for use in the diagnosis, cure, mitigation, treatment, or
             484      prevention of disease in humans or animals;
             485          (B) a substance that is required by any applicable federal or state law or rule to be
             486      dispensed by prescription only or is restricted to administration by practitioners only;
             487          (C) a substance other than food intended to affect the structure or any function of the
             488      body of humans or other animals; and
             489          (D) substances intended for use as a component of any substance specified in
             490      Subsections (1)(r)(i)(A), (B), and (C)[, and (D)].
             491          (ii) "Drug" does not include dietary supplements.
             492          (s) "Drug dependent person" means any individual who unlawfully and habitually uses


             493      any controlled substance to endanger the public morals, health, safety, or welfare, or who is so
             494      dependent upon the use of controlled substances as to have lost the power of self-control with
             495      reference to the individual's dependency.
             496          (t) "Food" means:
             497          (i) any nutrient or substance of plant, mineral, or animal origin other than a drug as
             498      specified in this chapter, and normally ingested by human beings; and
             499          (ii) foods for special dietary uses as exist by reason of a physical, physiological,
             500      pathological, or other condition including but not limited to the conditions of disease,
             501      convalescence, pregnancy, lactation, allergy, hypersensitivity to food, underweight, and
             502      overweight; uses for supplying a particular dietary need which exist by reason of age including
             503      but not limited to the ages of infancy and childbirth, and also uses for supplementing and for
             504      fortifying the ordinary or unusual diet with any vitamin, mineral, or other dietary property for
             505      use of a food. Any particular use of a food is a special dietary use regardless of the nutritional
             506      purposes.
             507          (u) "Immediate precursor" means a substance which the Attorney General of the United
             508      States has found to be, and by regulation designated as being, the principal compound used or
             509      produced primarily for use in the manufacture of a controlled substance, or which is an
             510      immediate chemical intermediary used or likely to be used in the manufacture of a controlled
             511      substance, the control of which is necessary to prevent, curtail, or limit the manufacture of the
             512      controlled substance.
             513          (v) "Indian" means a member of an Indian tribe.
             514          (w) "Indian religion" means any religion:
             515          (i) the origin and interpretation of which is from within a traditional Indian culture or
             516      community; and
             517          (ii) which is practiced by Indians.
             518          (x) "Indian tribe" means any tribe, band, nation, pueblo, or other organized group or
             519      community of Indians, including any Alaska Native village, which is legally recognized as
             520      eligible for and is consistent with the special programs, services, and entitlements provided by
             521      the United States to Indians because of their status as Indians.
             522          (y) "Manufacture" means the production, preparation, propagation, compounding, or
             523      processing of a controlled substance, either directly or indirectly by extraction from substances


             524      of natural origin, or independently by means of chemical synthesis or by a combination of
             525      extraction and chemical synthesis.
             526          (z) "Manufacturer" includes any person who packages, repackages, or labels any
             527      container of any controlled substance, except pharmacists who dispense or compound
             528      prescription orders for delivery to the ultimate consumer.
             529          (aa) "Marijuana" means all species of the genus cannabis and all parts of the genus,
             530      whether growing or not; the seeds of it; the resin extracted from any part of the plant; and every
             531      compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds, or
             532      resin. The term does not include the mature stalks of the plant, fiber produced from the stalks,
             533      oil or cake made from the seeds of the plant, any other compound, manufacture, salt,
             534      derivative, mixture, or preparation of the mature stalks, except the resin extracted from them,
             535      fiber, oil or cake, or the sterilized seed of the plant which is incapable of germination. Any
             536      synthetic equivalents of the substances contained in the plant cannabis sativa or any other
             537      species of the genus cannabis which are chemically indistinguishable and pharmacologically
             538      active are also included.
             539          (bb) "Money" means officially issued coin and currency of the United States or any
             540      foreign country.
             541          (cc) "Narcotic drug" means any of the following, whether produced directly or
             542      indirectly by extraction from substances of vegetable origin, or independently by means of
             543      chemical synthesis, or by a combination of extraction and chemical synthesis:
             544          (i) opium, coca leaves, and opiates;
             545          (ii) a compound, manufacture, salt, derivative, or preparation of opium, coca leaves, or
             546      opiates;
             547          (iii) opium poppy and poppy straw; or
             548          (iv) a substance, and any compound, manufacture, salt, derivative, or preparation of the
             549      substance, which is chemically identical with any of the substances referred to in Subsection
             550      (1)(cc)(i), (ii), or (iii), except narcotic drug does not include decocainized coca leaves or
             551      extracts of coca leaves which do not contain cocaine or ecgonine.
             552          (dd) "Negotiable instrument" means documents, containing an unconditional promise
             553      to pay a sum of money, which are legally transferable to another party by endorsement or
             554      delivery.


             555          (ee) "Opiate" means any drug or other substance having an addiction-forming or
             556      addiction-sustaining liability similar to morphine or being capable of conversion into a drug
             557      having addiction-forming or addiction-sustaining liability.
             558          (ff) "Opium poppy" means the plant of the species papaver somniferum L., except the
             559      seeds of the plant.
             560          (gg) "Person" means any corporation, association, partnership, trust, other institution or
             561      entity or one or more individuals.
             562          (hh) "Poppy straw" means all parts, except the seeds, of the opium poppy, after
             563      mowing.
             564          (ii) "Possession" or "use" means the joint or individual ownership, control, occupancy,
             565      holding, retaining, belonging, maintaining, or the application, inhalation, swallowing, injection,
             566      or consumption, as distinguished from distribution, of controlled substances and includes
             567      individual, joint, or group possession or use of controlled substances. For a person to be a
             568      possessor or user of a controlled substance, it is not required that the person be shown to have
             569      individually possessed, used, or controlled the substance, but it is sufficient if it is shown that
             570      the person jointly participated with one or more persons in the use, possession, or control of
             571      any substances with knowledge that the activity was occurring, or the controlled substance is
             572      found in a place or under circumstances indicating that the person had the ability and the intent
             573      to exercise dominion and control over it.
             574          (jj) "Practitioner" means a physician, dentist, naturopathic physician, veterinarian,
             575      pharmacist, scientific investigator, pharmacy, hospital, or other person licensed, registered, or
             576      otherwise permitted to distribute, dispense, conduct research with respect to, administer, or use
             577      in teaching or chemical analysis a controlled substance in the course of professional practice or
             578      research in this state.
             579          (kk) "Prescribe" means to issue a prescription:
             580          (i) orally or in writing; or
             581          (ii) by telephone, facsimile transmission, computer, or other electronic means of
             582      communication as defined by division rule.
             583          (ll) "Prescription" means an order issued:
             584          (i) by a licensed practitioner, in the course of that practitioner's professional practice or
             585      by collaborative pharmacy practice agreement; and


             586          (ii) for a controlled substance or other prescription drug or device for use by a patient
             587      or an animal.
             588          (mm) "Production" means the manufacture, planting, cultivation, growing, or
             589      harvesting of a controlled substance.
             590          (nn) "Securities" means any stocks, bonds, notes, or other evidences of debt or of
             591      property.
             592          (oo) "State" means the state of Utah.
             593          (pp) "Ultimate user" means any person who lawfully possesses a controlled substance
             594      for the person's own use, for the use of a member of the person's household, or for
             595      administration to an animal owned by the person or a member of the person's household.
             596          (2) If a term used in this chapter is not defined, the definition and terms of Title 76,
             597      Utah Criminal Code, shall apply.
             598          Section 4. Section 58-37-3 is amended to read:
             599           58-37-3. Controlled substances.
             600          (1) All substances listed in Section 58-37-4 or Section 58-37-4.2 are [considered]
             601      controlled.
             602          (2) All substances listed in the federal Controlled Substances Act, Title II, P.L. 91-513,
             603      are [considered] controlled.
             604          Section 5. Section 58-37-4 is amended to read:
             605           58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings
             606      required -- Specific substances included in schedules.
             607          (1) There are established five schedules of controlled substances known as Schedules I,
             608      II, III, IV, and V which [shall] consist of substances listed in this section.
             609          (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by
             610      the official name, common or usual name, chemical name, or brand name designated:
             611          (a) Schedule I:
             612          (i) Unless specifically excepted or unless listed in another schedule, any of the
             613      following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
             614      ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
             615      chemical designation:
             616          (A) Acetyl-alpha-methylfentanyl


             617      (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
             618          (B) Acetylmethadol;
             619          (C) Allylprodine;
             620          (D) Alphacetylmethadol, except levo-alphacetylmethadol also known as
             621      levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
             622          (E) Alphameprodine;
             623          (F) Alphamethadol;
             624          (G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
             625      propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
             626          (H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
             627      piperidinyl]-N-phenylpropanamide);
             628          (I) Benzethidine;
             629          (J) Betacetylmethadol;
             630          (K) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
             631      piperidinyl]-N-phenylpropanamide);
             632          (L) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
             633      phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
             634          (M) Betameprodine;
             635          (N) Betamethadol;
             636          (O) Betaprodine;
             637          (P) Clonitazene;
             638          (Q) Dextromoramide;
             639          (R) Diampromide;
             640          (S) Diethylthiambutene;
             641          (T) Difenoxin;
             642          (U) Dimenoxadol;
             643          (V) Dimepheptanol;
             644          (W) Dimethylthiambutene;
             645          (X) Dioxaphetyl butyrate;
             646          (Y) Dipipanone;
             647          (Z) Ethylmethylthiambutene;


             648          (AA) Etonitazene;
             649          (BB) Etoxeridine;
             650          (CC) Furethidine;
             651          (DD) Hydroxypethidine;
             652          (EE) Ketobemidone;
             653          (FF) Levomoramide;
             654          (GG) Levophenacylmorphan;
             655          (HH) Morpheridine;
             656          (II) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
             657          (JJ) Noracymethadol;
             658          (KK) Norlevorphanol;
             659          (LL) Normethadone;
             660          (MM) Norpipanone;
             661          (NN) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
             662      propanamide;
             663          (OO) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
             664          (PP) Phenadoxone;
             665          (QQ) Phenampromide;
             666          (RR) Phenomorphan;
             667          (SS) Phenoperidine;
             668          (TT) Piritramide;
             669          (UU) Proheptazine;
             670          (VV) Properidine;
             671          (WW) Propiram;
             672          (XX) Racemoramide;
             673          (YY) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
             674          (ZZ) Tilidine;
             675          (AAA) Trimeperidine;
             676          (BBB) 3-methylfentanyl, including the optical and geometric isomers
             677      (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
             678          (CCC) 3-methylthiofentanyl


             679      (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
             680          (ii) Unless specifically excepted or unless listed in another schedule, any of the
             681      following opium derivatives, their salts, isomers, and salts of isomers when the existence of the
             682      salts, isomers, and salts of isomers is possible within the specific chemical designation:
             683          (A) Acetorphine;
             684          (B) Acetyldihydrocodeine;
             685          (C) Benzylmorphine;
             686          (D) Codeine methylbromide;
             687          (E) Codeine-N-Oxide;
             688          (F) Cyprenorphine;
             689          (G) Desomorphine;
             690          (H) Dihydromorphine;
             691          (I) Drotebanol;
             692          (J) Etorphine (except hydrochloride salt);
             693          (K) Heroin;
             694          (L) Hydromorphinol;
             695          (M) Methyldesorphine;
             696          (N) Methylhydromorphine;
             697          (O) Morphine methylbromide;
             698          (P) Morphine methylsulfonate;
             699          (Q) Morphine-N-Oxide;
             700          (R) Myrophine;
             701          (S) Nicocodeine;
             702          (T) Nicomorphine;
             703          (U) Normorphine;
             704          (V) Pholcodine; and
             705          (W) Thebacon.
             706          (iii) Unless specifically excepted or unless listed in another schedule, any material,
             707      compound, mixture, or preparation which contains any quantity of the following hallucinogenic
             708      substances, or which contains any of their salts, isomers, and salts of isomers when the
             709      existence of the salts, isomers, and salts of isomers is possible within the specific chemical


             710      designation; as used in this Subsection (2)(iii) only, "isomer" includes the optical, position, and
             711      geometric isomers:
             712          (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
             713      .-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; .-ET; and AET;
             714          (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
             715      4-bromo-2,5-dimethoxy-.-methylphenethylamine; 4-bromo-2,5-DMA;
             716          (C) 4-bromo-2,5-dimethoxypenethylamine, some trade or other names:
             717      2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
             718          (D) 2,5-dimethoxyamphetamine, some trade or other names:
             719      2,5-dimethoxy-.-methylphenethylamine; 2,5-DMA;
             720          (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
             721          (F) 4-methoxyamphetamine, some trade or other names:
             722      4-methoxy-.-methylphenethylamine; paramethoxyamphetamine, PMA;
             723          (G) 5-methoxy-3,4-methylenedioxyamphetamine;
             724          (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
             725      4-methyl-2,5-dimethoxy-.-methylphenethylamine; "DOM"; and "STP";
             726          (I) 3,4-methylenedioxy amphetamine;
             727          (J) 3,4-methylenedioxymethamphetamine (MDMA);
             728          (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
             729      alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
             730          (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
             731      N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
             732          (M) 3,4,5-trimethoxy amphetamine;
             733          (N) Bufotenine, some trade and other names:
             734      3-(.-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,
             735      N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
             736          (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
             737          (P) Dimethyltryptamine, some trade or other names: DMT;
             738          (Q) Ibogaine, some trade and other names:
             739      7-Ethyl-6,6.,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
             740      [5,4-b] indole; Tabernanthe iboga;


             741          (R) Lysergic acid diethylamide;
             742          (S) Marijuana;
             743          (T) Mescaline;
             744          (U) Parahexyl, some trade or other names:
             745      3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
             746          (V) Peyote, meaning all parts of the plant presently classified botanically as
             747      Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from
             748      any part of such plant, and every compound, manufacture, salts, derivative, mixture, or
             749      preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
             750          (W) N-ethyl-3-piperidyl benzilate;
             751          (X) N-methyl-3-piperidyl benzilate;
             752          (Y) Psilocybin;
             753          (Z) Psilocyn;
             754          (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis
             755      (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis
             756      plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives,
             757      and their isomers with similar chemical structure and pharmacological activity to those
             758      substances contained in the plant, such as the following: .1 cis or trans tetrahydrocannabinol,
             759      and their optical isomers .6 cis or trans tetrahydrocannabinol, and their optical isomers .3,4
             760      cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
             761      substances is not internationally standardized, compounds of these structures, regardless of
             762      numerical designation of atomic positions covered;
             763          (BB) Ethylamine analog of phencyclidine, some trade or other names:
             764      N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
             765      N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
             766          (CC) Pyrrolidine analog of phencyclidine, some trade or other names:
             767      1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
             768          (DD) Thiophene analog of phencyclidine, some trade or other names:
             769      1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
             770          (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
             771          (iv) Unless specifically excepted or unless listed in another schedule, any material


             772      compound, mixture, or preparation which contains any quantity of the following substances
             773      having a depressant effect on the central nervous system, including its salts, isomers, and salts
             774      of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
             775      specific chemical designation:
             776          (A) Mecloqualone; and
             777          (B) Methaqualone.
             778          (v) Any material, compound, mixture, or preparation containing any quantity of the
             779      following substances having a stimulant effect on the central nervous system, including their
             780      salts, isomers, and salts of isomers:
             781          (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or
             782      4,5-dihydro-5-phenyl-2-oxazolamine;
             783          (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
             784      alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
             785          (C) Fenethylline;
             786          (D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
             787      alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
             788      alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;
             789      methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of
             790      optical isomers;
             791          (E) (.)cis-4-methylaminorex ((.)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
             792          (F) N-ethylamphetamine; and
             793          (G) N,N-dimethylamphetamine, also known as
             794      N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
             795          (vi) Any material, compound, mixture, or preparation which contains any quantity of
             796      the following substances, including their optical isomers, salts, and salts of isomers, subject to
             797      temporary emergency scheduling:
             798          (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
             799          (B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
             800          (vii) Unless specifically excepted or unless listed in another schedule, any material,
             801      compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate
             802      (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.


             803          (b) Schedule II:
             804          (i) Unless specifically excepted or unless listed in another schedule, any of the
             805      following substances whether produced directly or indirectly by extraction from substances of
             806      vegetable origin, or independently by means of chemical synthesis, or by a combination of
             807      extraction and chemical synthesis:
             808          (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
             809      opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone,
             810      and their respective salts, but including:
             811          (I) Raw opium;
             812          (II) Opium extracts;
             813          (III) Opium fluid;
             814          (IV) Powdered opium;
             815          (V) Granulated opium;
             816          (VI) Tincture of opium;
             817          (VII) Codeine;
             818          (VIII) Ethylmorphine;
             819          (IX) Etorphine hydrochloride;
             820          (X) Hydrocodone;
             821          (XI) Hydromorphone;
             822          (XII) Metopon;
             823          (XIII) Morphine;
             824          (XIV) Oxycodone;
             825          (XV) Oxymorphone; and
             826          (XVI) Thebaine;
             827          (B) Any salt, compound, derivative, or preparation which is chemically equivalent or
             828      identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
             829      substances may not include the isoquinoline alkaloids of opium;
             830          (C) Opium poppy and poppy straw;
             831          (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
             832      any salt, compound, derivative, or preparation which is chemically equivalent or identical with
             833      any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,


             834      and salts of isomers and derivatives, whether derived from the coca plant or synthetically
             835      produced, except the substances may not include decocainized coca leaves or extraction of coca
             836      leaves, which extractions do not contain cocaine or ecgonine; and
             837          (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either
             838      liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.
             839          (ii) Unless specifically excepted or unless listed in another schedule, any of the
             840      following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
             841      ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
             842      chemical designation, except dextrorphan and levopropoxyphene:
             843          (A) Alfentanil;
             844          (B) Alphaprodine;
             845          (C) Anileridine;
             846          (D) Bezitramide;
             847          (E) Bulk dextropropoxyphene (nondosage forms);
             848          (F) Carfentanil;
             849          (G) Dihydrocodeine;
             850          (H) Diphenoxylate;
             851          (I) Fentanyl;
             852          (J) Isomethadone;
             853          (K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,
             854      levomethadyl acetate, or LAAM;
             855          (L) Levomethorphan;
             856          (M) Levorphanol;
             857          (N) Metazocine;
             858          (O) Methadone;
             859          (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
             860          (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic
             861      acid;
             862          (R) Pethidine (meperidine);
             863          (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
             864          (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;


             865          (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
             866          (V) Phenazocine;
             867          (W) Piminodine;
             868          (X) Racemethorphan;
             869          (Y) Racemorphan;
             870          (Z) Remifentanil; and
             871          (AA) Sufentanil.
             872          (iii) Unless specifically excepted or unless listed in another schedule, any material,
             873      compound, mixture, or preparation which contains any quantity of the following substances
             874      having a stimulant effect on the central nervous system:
             875          (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
             876          (B) Methamphetamine, its salts, isomers, and salts of its isomers;
             877          (C) Phenmetrazine and its salts; and
             878          (D) Methylphenidate.
             879          (iv) Unless specifically excepted or unless listed in another schedule, any material,
             880      compound, mixture, or preparation which contains any quantity of the following substances
             881      having a depressant effect on the central nervous system, including its salts, isomers, and salts
             882      of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
             883      specific chemical designation:
             884          (A) Amobarbital;
             885          (B) Glutethimide;
             886          (C) Pentobarbital;
             887          (D) Phencyclidine;
             888          (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
             889      1-piperidinocyclohexanecarbonitrile (PCC); and
             890          (F) Secobarbital.
             891          (v) (A) Unless specifically excepted or unless listed in another schedule, any material,
             892      compound, mixture, or preparation which contains any quantity of Phenylacetone.
             893          (B) Some of these substances may be known by trade or other names:
             894      phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
             895          (vi) Nabilone, another name for nabilone:


             896      (.)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
             897      6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
             898          (c) Schedule III:
             899          (i) Unless specifically excepted or unless listed in another schedule, any material,
             900      compound, mixture, or preparation which contains any quantity of the following substances
             901      having a stimulant effect on the central nervous system, including its salts, isomers whether
             902      optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers,
             903      and salts of isomers is possible within the specific chemical designation:
             904          (A) Those compounds, mixtures, or preparations in dosage unit form containing any
             905      stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were
             906      listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the
             907      Code of Federal Regulations, and any other drug of the quantitive composition shown in that
             908      list for those drugs or which is the same except that it contains a lesser quantity of controlled
             909      substances;
             910          (B) Benzphetamine;
             911          (C) Chlorphentermine;
             912          (D) Clortermine; and
             913          (E) Phendimetrazine.
             914          (ii) Unless specifically excepted or unless listed in another schedule, any material,
             915      compound, mixture, or preparation which contains any quantity of the following substances
             916      having a depressant effect on the central nervous system:
             917          (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
             918      pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients
             919      which are not listed in any schedule;
             920          (B) Any suppository dosage form containing amobarbital, secobarbital, or
             921      pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug
             922      Administration for marketing only as a suppository;
             923          (C) Any substance which contains any quantity of a derivative of barbituric acid or any
             924      salt of any of them;
             925          (D) Chlorhexadol;
             926          (E) Buprenorphine;


             927          (F) Any drug product containing gamma hydroxybutyric acid, including its salts,
             928      isomers, and salts of isomers, for which an application is approved under the federal Food,
             929      Drug, and Cosmetic Act, Section 505;
             930          (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:
             931      . -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
             932          (H) Lysergic acid;
             933          (I) Lysergic acid amide;
             934          (J) Methyprylon;
             935          (K) Sulfondiethylmethane;
             936          (L) Sulfonethylmethane;
             937          (M) Sulfonmethane; and
             938          (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a
             939      tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
             940      2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
             941      4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
             942      flupyrazapon.
             943          (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
             944      U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
             945      (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or
             946      (-)-delta-9-(trans)-tetrahydrocannabinol.
             947          (iv) Nalorphine.
             948          (v) Unless specifically excepted or unless listed in another schedule, any material,
             949      compound, mixture, or preparation containing limited quantities of any of the following
             950      narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:
             951          (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
             952      milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of
             953      opium;
             954          (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
             955      milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
             956      therapeutic amounts;
             957          (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more


             958      than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline
             959      alkaloid of opium;
             960          (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
             961      than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
             962      recognized therapeutic amounts;
             963          (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90
             964      milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
             965      therapeutic amounts;
             966          (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
             967      than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
             968      recognized therapeutic amounts;
             969          (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
             970      more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
             971      recognized therapeutic amounts; and
             972          (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with
             973      one or more active, non-narcotic ingredients in recognized therapeutic amounts.
             974          (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids
             975      including any of the following or any isomer, ester, salt, or derivative of the following that
             976      promotes muscle growth:
             977          (A) Boldenone;
             978          (B) Chlorotestosterone (4-chlortestosterone);
             979          (C) Clostebol;
             980          (D) Dehydrochlormethyltestosterone;
             981          (E) Dihydrotestosterone (4-dihydrotestosterone);
             982          (F) Drostanolone;
             983          (G) Ethylestrenol;
             984          (H) Fluoxymesterone;
             985          (I) Formebulone (formebolone);
             986          (J) Mesterolone;
             987          (K) Methandienone;
             988          (L) Methandranone;


             989          (M) Methandriol;
             990          (N) Methandrostenolone;
             991          (O) Methenolone;
             992          (P) Methyltestosterone;
             993          (Q) Mibolerone;
             994          (R) Nandrolone;
             995          (S) Norethandrolone;
             996          (T) Oxandrolone;
             997          (U) Oxymesterone;
             998          (V) Oxymetholone;
             999          (W) Stanolone;
             1000          (X) Stanozolol;
             1001          (Y) Testolactone;
             1002          (Z) Testosterone; and
             1003          (AA) Trenbolone.
             1004          (vii) Anabolic steroids expressly intended for administration through implants to cattle
             1005      or other nonhuman species, and approved by the Secretary of Health and Human Services for
             1006      use, may not be classified as a controlled substance.
             1007          (d) Schedule IV:
             1008          (i) Unless specifically excepted or unless listed in another schedule, any material,
             1009      compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not
             1010      less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.
             1011          (ii) Unless specifically excepted or unless listed in another schedule, any material,
             1012      compound, mixture, or preparation which contains any quantity of the following substances,
             1013      including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and
             1014      salts of isomers is possible within the specific chemical designation:
             1015          (A) Alprazolam;
             1016          (B) Barbital;
             1017          (C) Bromazepam;
             1018          (D) Butorphanol;
             1019          (E) Camazepam;


             1020          (F) Carisoprodol;
             1021          (G) Chloral betaine;
             1022          (H) Chloral hydrate;
             1023          (I) Chlordiazepoxide;
             1024          (J) Clobazam;
             1025          (K) Clonazepam;
             1026          (L) Clorazepate;
             1027          (M) Clotiazepam;
             1028          (N) Cloxazolam;
             1029          (O) Delorazepam;
             1030          (P) Diazepam;
             1031          (Q) Dichloralphenazone;
             1032          (R) Estazolam;
             1033          (S) Ethchlorvynol;
             1034          (T) Ethinamate;
             1035          (U) Ethyl loflazepate;
             1036          (V) Fludiazepam;
             1037          (W) Flunitrazepam;
             1038          (X) Flurazepam;
             1039          (Y) Halazepam;
             1040          (Z) Haloxazolam;
             1041          (AA) Ketazolam;
             1042          (BB) Loprazolam;
             1043          (CC) Lorazepam;
             1044          (DD) Lormetazepam;
             1045          (EE) Mebutamate;
             1046          (FF) Medazepam;
             1047          (GG) Meprobamate;
             1048          (HH) Methohexital;
             1049          (II) Methylphenobarbital (mephobarbital);
             1050          (JJ) Midazolam;


             1051          (KK) Nimetazepam;
             1052          (LL) Nitrazepam;
             1053          (MM) Nordiazepam;
             1054          (NN) Oxazepam;
             1055          (OO) Oxazolam;
             1056          (PP) Paraldehyde;
             1057          (QQ) Pentazocine;
             1058          (RR) Petrichloral;
             1059          (SS) Phenobarbital;
             1060          (TT) Pinazepam;
             1061          (UU) Prazepam;
             1062          (VV) Quazepam;
             1063          (WW) Temazepam;
             1064          (XX) Tetrazepam;
             1065          (YY) Triazolam;
             1066          (ZZ) Zaleplon; and
             1067          (AAA) Zolpidem.
             1068          (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
             1069      any quantity of the following substances, including its salts, isomers whether optical, position,
             1070      or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of
             1071      isomers is possible.
             1072          (iv) Unless specifically excepted or unless listed in another schedule, any material,
             1073      compound, mixture, or preparation which contains any quantity of the following substances
             1074      having a stimulant effect on the central nervous system, including its salts, isomers whether
             1075      optical, position, or geometric isomers, and salts of the isomers when the existence of the salts,
             1076      isomers, and salts of isomers is possible within the specific chemical designation:
             1077          (A) Cathine ((+)-norpseudoephedrine);
             1078          (B) Diethylpropion;
             1079          (C) Fencamfamine;
             1080          (D) Fenproprex;
             1081          (E) Mazindol;


             1082          (F) Mefenorex;
             1083          (G) Modafinil;
             1084          (H) Pemoline, including organometallic complexes and chelates thereof;
             1085          (I) Phentermine;
             1086          (J) Pipradrol;
             1087          (K) Sibutramine; and
             1088          (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
             1089          (v) Unless specifically excepted or unless listed in another schedule, any material,
             1090      compound, mixture, or preparation which contains any quantity of dextropropoxyphene
             1091      (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
             1092          (e) Schedule V: Any compound, mixture, or preparation containing any of the
             1093      following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous
             1094      base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in
             1095      sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal
             1096      qualities other than those possessed by the narcotic drug alone:
             1097          (i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
             1098          (ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
             1099      grams;
             1100          (iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
             1101      grams;
             1102          (iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of
             1103      atropine sulfate per dosage unit;
             1104          (v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
             1105          (vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
             1106      atropine sulfate per dosage unit; and
             1107          (vii) unless specifically exempted or excluded or unless listed in another schedule, any
             1108      material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant
             1109      effect on the central nervous system, including its salts, isomers, and salts of isomers.
             1110          Section 6. Section 58-37-4.2 is enacted to read:
             1111          58-37-4.2. Listed controlled substances.
             1112          The following substances, their analogs, homologs, and synthetic equivalents are listed


             1113      controlled substances:
             1114          (1) AM-694;1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone;
             1115          (2) CP 47,497 and its C6, C8, and C9 homologs; 2-[(1R,3S)-3-hydroxycyclohexyl]
             1116      -5-(2-methyloctan-2-yl)phenol;
             1117          (3) HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
             1118      -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
             1119          (4) HU-211; Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
             1120      methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
             1121          (5) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
             1122          (6) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone {also known as
             1123      1-Pentyl-3-(1-naphthoyl)indole};
             1124          (7) JWH-019; 1-hexyl-3-(1-naphthoyl)indole;              1125          (8) JWH-073; Naphthalen-1-yl(1-butylindol-3-yl)methanone {also known as
             1126      1-Butyl-3-(1-naphthoyl)indole};
             1127          (9) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol- 3-yl)methanone;
             1128          (10) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);
             1129          (11) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl) indole;
             1130          (12) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;
             1131          (13) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone;
             1132          (14) JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole; and
             1133          (15) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole {also known as
             1134      BTW-8 and SR-18}.
             1135          Section 7. Section 58-37-6 is amended to read:
             1136           58-37-6. License to manufacture, produce, distribute, dispense, administer, or
             1137      conduct research -- Issuance by division -- Denial, suspension, or revocation -- Records
             1138      required -- Prescriptions.
             1139          (1) (a) The division may adopt rules relating to the licensing and control of the
             1140      manufacture, distribution, production, prescription, administration, dispensing, conducting of
             1141      research with, and performing of laboratory analysis upon controlled substances within this
             1142      state.
             1143          (b) The division may assess reasonable fees to defray the cost of issuing original and


             1144      renewal licenses under this chapter pursuant to Section 63J-1-504 .
             1145          (2) (a) (i) Every person who manufactures, produces, distributes, prescribes, dispenses,
             1146      administers, conducts research with, or performs laboratory analysis upon any controlled
             1147      substance in Schedules II through V within this state, or who proposes to engage in
             1148      manufacturing, producing, distributing, prescribing, dispensing, administering, conducting
             1149      research with, or performing laboratory analysis upon controlled substances included in
             1150      Schedules II through V within this state shall obtain a license issued by the division.
             1151          (ii) The division shall issue each license under this chapter in accordance with a
             1152      two-year renewal cycle established by rule. The division may by rule extend or shorten a
             1153      renewal period by as much as one year to stagger the renewal cycles it administers.
             1154          (b) Persons licensed to manufacture, produce, distribute, prescribe, dispense,
             1155      administer, conduct research with, or perform laboratory analysis upon controlled substances in
             1156      Schedules II through V within this state may possess, manufacture, produce, distribute,
             1157      prescribe, dispense, administer, conduct research with, or perform laboratory analysis upon
             1158      those substances to the extent authorized by their license and in conformity with this chapter.
             1159          (c) The following persons are not required to obtain a license and may lawfully possess
             1160      controlled substances under this section:
             1161          (i) an agent or employee, except a sales representative, of any registered manufacturer,
             1162      distributor, or dispenser of any controlled substance, if the agent or employee is acting in the
             1163      usual course of the person's business or employment; however, nothing in this subsection shall
             1164      be interpreted to permit an agent, employee, sales representative, or detail man to maintain an
             1165      inventory of controlled substances separate from the location of the person's employer's
             1166      registered and licensed place of business;
             1167          (ii) a motor carrier or warehouseman, or an employee of a motor carrier or
             1168      warehouseman, who possesses any controlled substance in the usual course of the person's
             1169      business or employment; and
             1170          (iii) an ultimate user, or any person who possesses any controlled substance pursuant to
             1171      a lawful order of a practitioner.
             1172          (d) The division may enact rules waiving the license requirement for certain
             1173      manufacturers, producers, distributors, prescribers, dispensers, administrators, research
             1174      practitioners, or laboratories performing analysis if consistent with the public health and safety.


             1175          (e) A separate license is required at each principal place of business or professional
             1176      practice where the applicant manufactures, produces, distributes, dispenses, conducts research
             1177      with, or performs laboratory analysis upon controlled substances.
             1178          (f) The division may enact rules providing for the inspection of a licensee or applicant's
             1179      establishment, and may inspect the establishment according to those rules.
             1180          (3) (a) Upon proper application, the division shall license a qualified applicant to
             1181      manufacture, produce, distribute, conduct research with, or perform laboratory analysis upon
             1182      controlled substances included in Schedules I through V, unless it determines that issuance of a
             1183      license is inconsistent with the public interest. The division shall not issue a license to any
             1184      person to prescribe, dispense, or administer a Schedule I controlled substance. In determining
             1185      public interest, the division shall consider whether or not the applicant has:
             1186          (i) maintained effective controls against diversion of controlled substances and any
             1187      Schedule I or II substance compounded from any controlled substance into other than
             1188      legitimate medical, scientific, or industrial channels;
             1189          (ii) complied with applicable state and local law;
             1190          (iii) been convicted under federal or state laws relating to the manufacture, distribution,
             1191      or dispensing of substances;
             1192          (iv) past experience in the manufacture of controlled dangerous substances;
             1193          (v) established effective controls against diversion; and
             1194          (vi) complied with any other factors that the division establishes that promote the
             1195      public health and safety.
             1196          (b) Licenses granted under Subsection (3)(a) do not entitle a licensee to manufacture,
             1197      produce, distribute, conduct research with, or perform laboratory analysis upon controlled
             1198      substances in Schedule I other than those specified in the license.
             1199          (c) (i) Practitioners shall be licensed to administer, dispense, or conduct research with
             1200      substances in Schedules II through V if they are authorized to administer, dispense, or conduct
             1201      research under the laws of this state.
             1202          (ii) The division need not require a separate license for practitioners engaging in
             1203      research with nonnarcotic controlled substances in Schedules II through V where the licensee is
             1204      already licensed under this chapter in another capacity.
             1205          (iii) With respect to research involving narcotic substances in Schedules II through V,


             1206      or where the division by rule requires a separate license for research of nonnarcotic substances
             1207      in Schedules II through V, a practitioner shall apply to the division prior to conducting
             1208      research.
             1209          (iv) Licensing for purposes of bona fide research with controlled substances by a
             1210      practitioner considered qualified may be denied only on a ground specified in Subsection (4),
             1211      or upon evidence that the applicant will abuse or unlawfully transfer or fail to safeguard
             1212      adequately the practitioner's supply of substances against diversion from medical or scientific
             1213      use.
             1214          (v) Practitioners registered under federal law to conduct research in Schedule I
             1215      substances may conduct research in Schedule I substances within this state upon furnishing the
             1216      division evidence of federal registration.
             1217          (d) Compliance by manufacturers, producers, and distributors with the provisions of
             1218      federal law respecting registration, excluding fees, entitles them to be licensed under this
             1219      chapter.
             1220          (e) The division shall initially license those persons who own or operate an
             1221      establishment engaged in the manufacture, production, distribution, dispensation, or
             1222      administration of controlled substances prior to April 3, 1980, and who are licensed by the
             1223      state.
             1224          (4) (a) Any license pursuant to Subsection (2) or (3) may be denied, suspended, placed
             1225      on probation, or revoked by the division upon finding that the applicant or licensee has:
             1226          (i) materially falsified any application filed or required pursuant to this chapter;
             1227          (ii) been convicted of an offense under this chapter or any law of the United States, or
             1228      any state, relating to any substance defined as a controlled substance;
             1229          (iii) been convicted of a felony under any other law of the United States or any state
             1230      within five years of the date of the issuance of the license;
             1231          (iv) had a federal license denied, suspended, or revoked by competent federal authority
             1232      and is no longer authorized to engage in the manufacturing, distribution, or dispensing of
             1233      controlled substances;
             1234          (v) had the licensee's license suspended or revoked by competent authority of another
             1235      state for violation of laws or regulations comparable to those of this state relating to the
             1236      manufacture, distribution, or dispensing of controlled substances;


             1237          (vi) violated any division rule that reflects adversely on the licensee's reliability and
             1238      integrity with respect to controlled substances;
             1239          (vii) refused inspection of records required to be maintained under this chapter by a
             1240      person authorized to inspect them; or
             1241          (viii) prescribed, dispensed, administered, or injected an anabolic steroid for the
             1242      purpose of manipulating human hormonal structure so as to:
             1243          (A) increase muscle mass, strength, or weight without medical necessity and without a
             1244      written prescription by any practitioner in the course of the practitioner's professional practice;
             1245      or
             1246          (B) improve performance in any form of human exercise, sport, or game.
             1247          (b) The division may limit revocation or suspension of a license to a particular
             1248      controlled substance with respect to which grounds for revocation or suspension exist.
             1249          (c) (i) Proceedings to deny, revoke, or suspend a license shall be conducted pursuant to
             1250      this section and in accordance with the procedures set forth in Title 58, Chapter 1, Division of
             1251      Occupational and Professional Licensing Act, and conducted in conjunction with the
             1252      appropriate representative committee designated by the director of the department.
             1253          (ii) Nothing in this Subsection (4)(c) gives the Division of Occupational and
             1254      Professional Licensing exclusive authority in proceedings to deny, revoke, or suspend licenses,
             1255      except where the division is designated by law to perform those functions, or, when not
             1256      designated by law, is designated by the executive director of the Department of Commerce to
             1257      conduct the proceedings.
             1258          (d) (i) The division may suspend any license simultaneously with the institution of
             1259      proceedings under this section if it finds there is an imminent danger to the public health or
             1260      safety.
             1261          (ii) Suspension shall continue in effect until the conclusion of proceedings, including
             1262      judicial review, unless withdrawn by the division or dissolved by a court of competent
             1263      jurisdiction.
             1264          (e) (i) If a license is suspended or revoked under this Subsection (4), all controlled
             1265      substances owned or possessed by the licensee may be placed under seal in the discretion of the
             1266      division.
             1267          (ii) Disposition may not be made of substances under seal until the time for taking an


             1268      appeal has lapsed, or until all appeals have been concluded, unless a court, upon application,
             1269      orders the sale of perishable substances and the proceeds deposited with the court.
             1270          (iii) If a revocation order becomes final, all controlled substances shall be forfeited.
             1271          (f) The division shall notify promptly the Drug Enforcement Administration of all
             1272      orders suspending or revoking a license and all forfeitures of controlled substances.
             1273          (5) (a) Persons licensed under Subsection (2) or (3) shall maintain records and
             1274      inventories in conformance with the record keeping and inventory requirements of federal and
             1275      state law and any additional rules issued by the division.
             1276          (b) (i) Every physician, dentist, naturopathic physician, veterinarian, practitioner, or
             1277      other person who is authorized to administer or professionally use a controlled substance shall
             1278      keep a record of the drugs received by him and a record of all drugs administered, dispensed, or
             1279      professionally used by him otherwise than by a prescription.
             1280          (ii) A person using small quantities or solutions or other preparations of those drugs for
             1281      local application has complied with this Subsection (5)(b) if the person keeps a record of the
             1282      quantity, character, and potency of those solutions or preparations purchased or prepared by
             1283      him, and of the dates when purchased or prepared.
             1284          (6) Controlled substances in Schedules I through V may be distributed only by a
             1285      licensee and pursuant to an order form prepared in compliance with division rules or a lawful
             1286      order under the rules and regulations of the United States.
             1287          (7) (a) A person may not write or authorize a prescription for a controlled substance
             1288      unless the person is:
             1289          (i) a practitioner authorized to prescribe drugs and medicine under the laws of this state
             1290      or under the laws of another state having similar standards; and
             1291          (ii) licensed under this chapter or under the laws of another state having similar
             1292      standards.
             1293          (b) A person other than a pharmacist licensed under the laws of this state, or the
             1294      pharmacist's licensed intern, as required by Sections 58-17b-303 and 58-17b-304 , may not
             1295      dispense a controlled substance.
             1296          (c) (i) A controlled substance may not be dispensed without the written prescription of
             1297      a practitioner, if the written prescription is required by the federal Controlled Substances Act.
             1298          (ii) That written prescription shall be made in accordance with Subsection (7)(a) and in


             1299      conformity with Subsection (7)(d).
             1300          (iii) In emergency situations, as defined by division rule, controlled substances may be
             1301      dispensed upon oral prescription of a practitioner, if reduced promptly to writing on forms
             1302      designated by the division and filed by the pharmacy.
             1303          (iv) Prescriptions reduced to writing by a pharmacist shall be in conformity with
             1304      Subsection (7)(d).
             1305          (d) Except for emergency situations designated by the division, a person may not issue,
             1306      fill, compound, or dispense a prescription for a controlled substance unless the prescription is
             1307      signed by the prescriber in ink or indelible pencil or is signed with an electronic signature of
             1308      the prescriber as authorized by division rule, and contains the following information:
             1309          (i) the name, address, and registry number of the prescriber;
             1310          (ii) the name, address, and age of the person to whom or for whom the prescription is
             1311      issued;
             1312          (iii) the date of issuance of the prescription; and
             1313          (iv) the name, quantity, and specific directions for use by the ultimate user of the
             1314      controlled substance.
             1315          (e) A prescription may not be written, issued, filled, or dispensed for a Schedule I
             1316      controlled substance.
             1317          (f) Except when administered directly to an ultimate user by a licensed practitioner,
             1318      controlled substances are subject to the following restrictions:
             1319          (i) (A) A prescription for a Schedule II substance may not be refilled.
             1320          (B) A Schedule II controlled substance may not be filled in a quantity to exceed a
             1321      one-month's supply, as directed on the daily dosage rate of the prescriptions.
             1322          (ii) A Schedule III or IV controlled substance may be filled only within six months of
             1323      issuance, and may not be refilled more than six months after the date of its original issuance or
             1324      be refilled more than five times after the date of the prescription unless renewed by the
             1325      practitioner.
             1326          (iii) All other controlled substances in Schedule V may be refilled as the prescriber's
             1327      prescription directs, but they may not be refilled one year after the date the prescription was
             1328      issued unless renewed by the practitioner.
             1329          (iv) Any prescription for a Schedule II substance may not be dispensed if it is not


             1330      presented to a pharmacist for dispensing by a pharmacist or a pharmacy intern within 30 days
             1331      after the date the prescription was issued, or 30 days after the dispensing date, if that date is
             1332      specified separately from the date of issue.
             1333          (v) A practitioner may issue more than one prescription at the same time for the same
             1334      Schedule II controlled substance, but only under the following conditions:
             1335          (A) no more than three prescriptions for the same Schedule II controlled substance may
             1336      be issued at the same time;
             1337          (B) no one prescription may exceed a 30-day supply;
             1338          (C) a second or third prescription shall include the date of issuance and the date for
             1339      dispensing; and
             1340          (D) unless the practitioner determines there is a valid medical reason to the contrary,
             1341      the date for dispensing a second or third prescription may not be fewer than 30 days from the
             1342      dispensing date of the previous prescription.
             1343          (vi) Each prescription for a controlled substance may contain only one controlled
             1344      substance per prescription form and may not contain any other legend drug or prescription
             1345      item.
             1346          (g) An order for a controlled substance in Schedules II through V for use by an
             1347      inpatient or an outpatient of a licensed hospital is exempt from all requirements of this
             1348      Subsection (7) if the order is:
             1349          (i) issued or made by a prescribing practitioner who holds an unrestricted registration
             1350      with the federal Drug Enforcement Administration, and an active Utah controlled substance
             1351      license in good standing issued by the division under this section, or a medical resident who is
             1352      exempted from licensure under Subsection 58-1-307 (1)(c);
             1353          (ii) authorized by the prescribing practitioner treating the patient and the prescribing
             1354      practitioner designates the quantity ordered;
             1355          (iii) entered upon the record of the patient, the record is signed by the prescriber
             1356      affirming the prescriber's authorization of the order within 48 hours after filling or
             1357      administering the order, and the patient's record reflects the quantity actually administered; and
             1358          (iv) filled and dispensed by a pharmacist practicing the pharmacist's profession within
             1359      the physical structure of the hospital, or the order is taken from a supply lawfully maintained by
             1360      the hospital and the amount taken from the supply is administered directly to the patient


             1361      authorized to receive it.
             1362          (h) A practitioner licensed under this chapter may not prescribe, administer, or
             1363      dispense a controlled substance to a child, without first obtaining the consent required in
             1364      Section 78B-3-406 of a parent, guardian, or person standing in loco parentis of the child except
             1365      in cases of an emergency. For purposes of this Subsection (7)(h), "child" has the same
             1366      meaning as defined in Section 78A-6-105 , and "emergency" means any physical condition
             1367      requiring the administration of a controlled substance for immediate relief of pain or suffering.
             1368          (i) A practitioner licensed under this chapter may not prescribe or administer dosages
             1369      of a controlled substance in excess of medically recognized quantities necessary to treat the
             1370      ailment, malady, or condition of the ultimate user.
             1371          (j) A practitioner licensed under this chapter may not prescribe, administer, or dispense
             1372      any controlled substance to another person knowing that the other person is using a false name,
             1373      address, or other personal information for the purpose of securing the controlled substance.
             1374          (k) A person who is licensed under this chapter to manufacture, distribute, or dispense
             1375      a controlled substance may not manufacture, distribute, or dispense a controlled substance to
             1376      another licensee or any other authorized person not authorized by this license.
             1377          (l) A person licensed under this chapter may not omit, remove, alter, or obliterate a
             1378      symbol required by this chapter or by a rule issued under this chapter.
             1379          (m) A person licensed under this chapter may not refuse or fail to make, keep, or
             1380      furnish any record notification, order form, statement, invoice, or information required under
             1381      this chapter.
             1382          (n) A person licensed under this chapter may not refuse entry into any premises for
             1383      inspection as authorized by this chapter.
             1384          (o) A person licensed under this chapter may not furnish false or fraudulent material
             1385      information in any application, report, or other document required to be kept by this chapter or
             1386      willfully make any false statement in any prescription, order, report, or record required by this
             1387      chapter.
             1388          (8) (a) (i) Any person licensed under this chapter who is found by the division to have
             1389      violated any of the provisions of Subsections (7)(k) through (7)(o) or Subsection (10) is subject
             1390      to a penalty not to exceed $5,000. The division shall determine the procedure for adjudication
             1391      of any violations in accordance with Sections 58-1-106 and 58-1-108 .


             1392          (ii) The division shall deposit all penalties collected under Subsection (8)(a)(i) in the
             1393      General Fund as a dedicated credit to be used by the division under Subsection 58-37f-502 (1).
             1394          (b) Any person who knowingly and intentionally violates Subsections (7)(h) through
             1395      (7)(j) or Subsection (10) is:
             1396          (i) upon first conviction, guilty of a class B misdemeanor;
             1397          (ii) upon second conviction, guilty of a class A misdemeanor; and
             1398          (iii) on third or subsequent conviction, guilty of a third degree felony.
             1399          (c) Any person who knowingly and intentionally violates Subsections (7)(k) through
             1400      (7)(o) shall upon conviction be guilty of a third degree felony.
             1401          (9) Any information communicated to any licensed practitioner in an attempt to
             1402      unlawfully procure, or to procure the administration of, a controlled substance is not considered
             1403      to be a privileged communication.
             1404          (10) A person holding a valid license under this chapter who is engaged in medical
             1405      research may produce, possess, or administer, but may not prescribe or dispense, a controlled
             1406      substance listed in Section 58-37-4.2 .
             1407          Section 8. Section 58-37-8 is amended to read:
             1408           58-37-8. Prohibited acts -- Penalties.
             1409          (1) Prohibited acts A -- Penalties:
             1410          (a) Except as authorized by this chapter, it is unlawful for any person to knowingly and
             1411      intentionally:
             1412          (i) produce, manufacture, or dispense, or to possess with intent to produce,
             1413      manufacture, or dispense, a controlled or counterfeit substance;
             1414          (ii) distribute a controlled or counterfeit substance, or to agree, consent, offer, or
             1415      arrange to distribute a controlled or counterfeit substance;
             1416          (iii) possess a controlled or counterfeit substance with intent to distribute; or
             1417          (iv) engage in a continuing criminal enterprise where:
             1418          (A) the person participates, directs, or engages in conduct which results in any
             1419      violation of any provision of Title 58, Chapters 37, 37a, 37b, 37c, or 37d that is a felony; and
             1420          (B) the violation is a part of a continuing series of two or more violations of Title 58,
             1421      Chapters 37, 37a, 37b, 37c, or 37d on separate occasions that are undertaken in concert with
             1422      five or more persons with respect to whom the person occupies a position of organizer,


             1423      supervisor, or any other position of management.
             1424          (b) Any person convicted of violating Subsection (1)(a) with respect to:
             1425          (i) a substance or a counterfeit of a substance classified in Schedule I or II, a controlled
             1426      substance analog, or gammahydroxybutyric acid as listed in Schedule III is guilty of a second
             1427      degree felony and upon a second or subsequent conviction is guilty of a first degree felony;
             1428          (ii) a substance or a counterfeit of a substance classified in Schedule III or IV, or
             1429      marijuana, or a substance listed in Section 58-37-4.2 is guilty of a third degree felony, and
             1430      upon a second or subsequent conviction is guilty of a second degree felony; or
             1431          (iii) a substance or a counterfeit of a substance classified in Schedule V is guilty of a
             1432      class A misdemeanor and upon a second or subsequent conviction is guilty of a third degree
             1433      felony.
             1434          (c) Any person who has been convicted of a violation of Subsection (1)(a)(ii) or (iii)
             1435      may be sentenced to imprisonment for an indeterminate term as provided by law, but if the trier
             1436      of fact finds a firearm as defined in Section 76-10-501 was used, carried, or possessed on his
             1437      person or in his immediate possession during the commission or in furtherance of the offense,
             1438      the court shall additionally sentence the person convicted for a term of one year to run
             1439      consecutively and not concurrently; and the court may additionally sentence the person
             1440      convicted for an indeterminate term not to exceed five years to run consecutively and not
             1441      concurrently.
             1442          (d) Any person convicted of violating Subsection (1)(a)(iv) is guilty of a first degree
             1443      felony punishable by imprisonment for an indeterminate term of not less than seven years and
             1444      which may be for life. Imposition or execution of the sentence may not be suspended, and the
             1445      person is not eligible for probation.
             1446          (2) Prohibited acts B -- Penalties:
             1447          (a) It is unlawful:
             1448          (i) for any person knowingly and intentionally to possess or use a controlled substance
             1449      analog or a controlled substance, unless it was obtained under a valid prescription or order,
             1450      directly from a practitioner while acting in the course of the person's professional practice, or as
             1451      otherwise authorized by this chapter;
             1452          (ii) for any owner, tenant, licensee, or person in control of any building, room,
             1453      tenement, vehicle, boat, aircraft, or other place knowingly and intentionally to permit them to


             1454      be occupied by persons unlawfully possessing, using, or distributing controlled substances in
             1455      any of those locations; or
             1456          (iii) for any person knowingly and intentionally to possess an altered or forged
             1457      prescription or written order for a controlled substance.
             1458          (b) Any person convicted of violating Subsection (2)(a)(i) with respect to:
             1459          (i) marijuana, if the amount is 100 pounds or more, is guilty of a second degree felony;
             1460          (ii) a substance classified in Schedule I or II, marijuana, if the amount is more than 16
             1461      ounces, but less than 100 pounds, or a controlled substance analog, is guilty of a third degree
             1462      felony; or
             1463          (iii) marijuana, if the marijuana is not in the form of an extracted resin from any part of
             1464      the plant, and the amount is more than one ounce but less than 16 ounces, is guilty of a class A
             1465      misdemeanor.
             1466          (c) Upon a person's conviction of a violation of this Subsection (2) subsequent to a
             1467      conviction under Subsection (1)(a), that person shall be sentenced to a one degree greater
             1468      penalty than provided in this Subsection (2).
             1469          (d) Any person who violates Subsection (2)(a)(i) with respect to all other controlled
             1470      substances not included in Subsection (2)(b)(i), (ii), or (iii), including a substance listed in
             1471      Section 58-37-4.2 , or less than one ounce of marijuana, is guilty of a class B misdemeanor.
             1472      Upon a second conviction the person is guilty of a class A misdemeanor, and upon a third or
             1473      subsequent conviction the person is guilty of a third degree felony.
             1474          (e) Any person convicted of violating Subsection (2)(a)(i) while inside the exterior
             1475      boundaries of property occupied by any correctional facility as defined in Section 64-13-1 or
             1476      any public jail or other place of confinement shall be sentenced to a penalty one degree greater
             1477      than provided in Subsection (2)(b), and if the conviction is with respect to controlled
             1478      substances as listed in:
             1479          (i) Subsection (2)(b), the person may be sentenced to imprisonment for an
             1480      indeterminate term as provided by law, and:
             1481          (A) the court shall additionally sentence the person convicted to a term of one year to
             1482      run consecutively and not concurrently; and
             1483          (B) the court may additionally sentence the person convicted for an indeterminate term
             1484      not to exceed five years to run consecutively and not concurrently; and


             1485          (ii) Subsection (2)(d), the person may be sentenced to imprisonment for an
             1486      indeterminate term as provided by law, and the court shall additionally sentence the person
             1487      convicted to a term of six months to run consecutively and not concurrently.
             1488          (f) Any person convicted of violating Subsection (2)(a)(ii) or [(2)(a)](iii) is:
             1489          (i) on a first conviction, guilty of a class B misdemeanor;
             1490          (ii) on a second conviction, guilty of a class A misdemeanor; and
             1491          (iii) on a third or subsequent conviction, guilty of a third degree felony.
             1492          (g) A person is subject to the penalties under Subsection (2)(h) who, in an offense not
             1493      amounting to a violation of Section 76-5-207 :
             1494          (i) violates Subsection (2)(a)(i) by knowingly and intentionally having in the person's
             1495      body any measurable amount of a controlled substance; and
             1496          (ii) operates a motor vehicle as defined in Section 76-5-207 in a negligent manner,
             1497      causing serious bodily injury as defined in Section 76-1-601 or the death of another.
             1498          (h) A person who violates Subsection (2)(g) by having in the person's body:
             1499          (i) a controlled substance classified under Schedule I, other than those described in
             1500      Subsection (2)(h)(ii), or a controlled substance classified under Schedule II is guilty of a second
             1501      degree felony;
             1502          (ii) marijuana, tetrahydrocannabinols, or equivalents described in Subsection
             1503      58-37-4 (2)(a)(iii)(S) or (AA), or a substance listed in Section 58-37-4.2 is guilty of a third
             1504      degree felony; or
             1505          (iii) any controlled substance classified under Schedules III, IV, or V is guilty of a class
             1506      A misdemeanor.
             1507          (i) A person is guilty of a separate offense for each victim suffering serious bodily
             1508      injury or death as a result of the person's negligent driving in violation of Subsection
             1509      58-37-8 (2)(g) whether or not the injuries arise from the same episode of driving.
             1510          (3) Prohibited acts C -- Penalties:
             1511          (a) It is unlawful for any person knowingly and intentionally:
             1512          (i) to use in the course of the manufacture or distribution of a controlled substance a
             1513      license number which is fictitious, revoked, suspended, or issued to another person or, for the
             1514      purpose of obtaining a controlled substance, to assume the title of, or represent oneself to be, a
             1515      manufacturer, wholesaler, apothecary, physician, dentist, veterinarian, or other authorized


             1516      person;
             1517          (ii) to acquire or obtain possession of, to procure or attempt to procure the
             1518      administration of, to obtain a prescription for, to prescribe or dispense to any person known to
             1519      be attempting to acquire or obtain possession of, or to procure the administration of any
             1520      controlled substance by misrepresentation or failure by the person to disclose receiving any
             1521      controlled substance from another source, fraud, forgery, deception, subterfuge, alteration of a
             1522      prescription or written order for a controlled substance, or the use of a false name or address;
             1523          (iii) to make any false or forged prescription or written order for a controlled substance,
             1524      or to utter the same, or to alter any prescription or written order issued or written under the
             1525      terms of this chapter; or
             1526          (iv) to make, distribute, or possess any punch, die, plate, stone, or other thing designed
             1527      to print, imprint, or reproduce the trademark, trade name, or other identifying mark, imprint, or
             1528      device of another or any likeness of any of the foregoing upon any drug or container or labeling
             1529      so as to render any drug a counterfeit controlled substance.
             1530          (b) Any person convicted of violating Subsection (3)(a) is guilty of a third degree
             1531      felony.
             1532          (4) Prohibited acts D -- Penalties:
             1533          (a) Notwithstanding other provisions of this section, a person not authorized under this
             1534      chapter who commits any act declared to be unlawful under this section, Title 58, Chapter 37a,
             1535      Utah Drug Paraphernalia Act, or under Title 58, Chapter 37b, Imitation Controlled Substances
             1536      Act, is upon conviction subject to the penalties and classifications under this Subsection (4) if
             1537      the trier of fact finds the act is committed:
             1538          (i) in a public or private elementary or secondary school or on the grounds of any of
             1539      those schools;
             1540          (ii) in a public or private vocational school or postsecondary institution or on the
             1541      grounds of any of those schools or institutions;
             1542          (iii) in those portions of any building, park, stadium, or other structure or grounds
             1543      which are, at the time of the act, being used for an activity sponsored by or through a school or
             1544      institution under Subsections (4)(a)(i) and (ii);
             1545          (iv) in or on the grounds of a preschool or child-care facility;
             1546          (v) in a public park, amusement park, arcade, or recreation center;


             1547          (vi) in or on the grounds of a house of worship as defined in Section 76-10-501 ;
             1548          (vii) in a shopping mall, sports facility, stadium, arena, theater, movie house,
             1549      playhouse, or parking lot or structure adjacent thereto;
             1550          (viii) in or on the grounds of a library;
             1551          (ix) within any area that is within 1,000 feet of any structure, facility, or grounds
             1552      included in Subsections (4)(a)(i), (ii), (iv), (vi), and (vii);
             1553          (x) in the presence of a person younger than 18 years of age, regardless of where the act
             1554      occurs; or
             1555          (xi) for the purpose of facilitating, arranging, or causing the transport, delivery, or
             1556      distribution of a substance in violation of this section to an inmate or on the grounds of any
             1557      correctional facility as defined in Section 76-8-311.3 .
             1558          (b) (i) A person convicted under this Subsection (4) is guilty of a first degree felony
             1559      and shall be imprisoned for a term of not less than five years if the penalty that would
             1560      otherwise have been established but for this Subsection (4) would have been a first degree
             1561      felony.
             1562          (ii) Imposition or execution of the sentence may not be suspended, and the person is
             1563      not eligible for probation.
             1564          (c) If the classification that would otherwise have been established would have been
             1565      less than a first degree felony but for this Subsection (4), a person convicted under this
             1566      Subsection (4) is guilty of one degree more than the maximum penalty prescribed for that
             1567      offense. This Subsection (4)(c) does not apply to a violation of Subsection (2)(g).
             1568          (d) (i) If the violation is of Subsection (4)(a)(xi):
             1569          (A) the person may be sentenced to imprisonment for an indeterminate term as
             1570      provided by law, and the court shall additionally sentence the person convicted for a term of
             1571      one year to run consecutively and not concurrently; and
             1572          (B) the court may additionally sentence the person convicted for an indeterminate term
             1573      not to exceed five years to run consecutively and not concurrently; and
             1574          (ii) the penalties under this Subsection (4)(d) apply also to any person who, acting with
             1575      the mental state required for the commission of an offense, directly or indirectly solicits,
             1576      requests, commands, coerces, encourages, or intentionally aids another person to commit a
             1577      violation of Subsection (4)(a)(xi).


             1578          (e) It is not a defense to a prosecution under this Subsection (4) that the actor
             1579      mistakenly believed the individual to be 18 years of age or older at the time of the offense or
             1580      was unaware of the individual's true age; nor that the actor mistakenly believed that the
             1581      location where the act occurred was not as described in Subsection (4)(a) or was unaware that
             1582      the location where the act occurred was as described in Subsection (4)(a).
             1583          (5) Any violation of this chapter for which no penalty is specified is a class B
             1584      misdemeanor.
             1585          (6) For purposes of penalty enhancement under Subsections (1)(b) and (2)(c), a plea of
             1586      guilty or no contest to a violation of this section which is held in abeyance under Title 77,
             1587      Chapter 2a, Pleas in Abeyance, is the equivalent of a conviction, even if the charge has been
             1588      subsequently reduced or dismissed in accordance with the plea in abeyance agreement.
             1589          (7) A person may be charged and sentenced for a violation of this section,
             1590      notwithstanding a charge and sentence for a violation of any other section of this chapter.
             1591          (8) (a) Any penalty imposed for violation of this section is in addition to, and not in
             1592      lieu of, any civil or administrative penalty or sanction authorized by law.
             1593          (b) Where violation of this chapter violates a federal law or the law of another state,
             1594      conviction or acquittal under federal law or the law of another state for the same act is a bar to
             1595      prosecution in this state.
             1596          (9) In any prosecution for a violation of this chapter, evidence or proof which shows a
             1597      person or persons produced, manufactured, possessed, distributed, or dispensed a controlled
             1598      substance or substances, is prima facie evidence that the person or persons did so with
             1599      knowledge of the character of the substance or substances.
             1600          (10) This section does not prohibit a veterinarian, in good faith and in the course of the
             1601      veterinarian's professional practice only and not for humans, from prescribing, dispensing, or
             1602      administering controlled substances or from causing the substances to be administered by an
             1603      assistant or orderly under the veterinarian's direction and supervision.
             1604          (11) Civil or criminal liability may not be imposed under this section on:
             1605          (a) any person registered under this chapter who manufactures, distributes, or possesses
             1606      an imitation controlled substance for use as a placebo or investigational new drug by a
             1607      registered practitioner in the ordinary course of professional practice or research; or
             1608          (b) any law enforcement officer acting in the course and legitimate scope of the


             1609      officer's employment.
             1610          (12) (a) Civil or criminal liability may not be imposed under this section on any Indian,
             1611      as defined in Subsection 58-37-2 (1)(v), who uses, possesses, or transports peyote for bona fide
             1612      traditional ceremonial purposes in connection with the practice of a traditional Indian religion
             1613      as defined in Subsection 58-37-2 (1)(w).
             1614          (b) In a prosecution alleging violation of this section regarding peyote as defined in
             1615      Subsection 58-37-4 (2)(a)(iii)(V), it is an affirmative defense that the peyote was used,
             1616      possessed, or transported by an Indian for bona fide traditional ceremonial purposes in
             1617      connection with the practice of a traditional Indian religion.
             1618          (c) (i) The defendant shall provide written notice of intent to claim an affirmative
             1619      defense under this Subsection (12) as soon as practicable, but not later than 10 days prior to
             1620      trial.
             1621          (ii) The notice shall include the specific claims of the affirmative defense.
             1622          (iii) The court may waive the notice requirement in the interest of justice for good
             1623      cause shown, if the prosecutor is not unfairly prejudiced by the lack of timely notice.
             1624          (d) The defendant shall establish the affirmative defense under this Subsection (12) by
             1625      a preponderance of the evidence. If the defense is established, it is a complete defense to the
             1626      charges.
             1627          (13) (a) It is an affirmative defense that the person produced, possessed, or
             1628      administered a controlled substance listed in Section 58-37-4.2 if the person:
             1629          (i) was engaged in medical research; and
             1630          (ii) was a holder of a valid license to possess controlled substances under Section
             1631      58-37-6 .
             1632          (b) It is not a defense under Subsection 58-37-8 (13)(a) that the person prescribed or
             1633      dispensed a controlled substance listed in 58-37-4.2 .
             1634          (14) It is an affirmative defense that the person possessed, in the person's body, a
             1635      controlled substance listed in Section 58-37-4.2 if:
             1636          (a) the person was the subject of medical research conducted by a holder of a valid
             1637      license to possess controlled substances under Section 58-37-6 ; and
             1638          (b) the substance was administered to the person by the medical researcher.
             1639          [(13)] (15) If any provision of this chapter, or the application of any provision to any


             1640      person or circumstances, is held invalid, the remainder of this chapter shall be given effect
             1641      without the invalid provision or application.
             1642          (16) A legislative body of a political subdivision may not enact an ordinance that is
             1643      less restrictive than any provision of this chapter.
             1644          Section 9. Section 58-38a-203 is amended to read:
             1645           58-38a-203. Duties of the committee.
             1646          (1) The committee serves as a consultative and advisory body to the Legislature
             1647      regarding:
             1648          (a) the movement of a controlled substance from one schedule or list to another;
             1649          (b) the removal of a controlled substance from any schedule or list; and
             1650          (c) the designation of a substance as a controlled substance and the placement of the
             1651      substance in a designated schedule or list.
             1652          (2) On or before September 30 of each year, the committee shall submit to the Health
             1653      and Human Services Interim Committee a written report:
             1654          (a) [listing] describing any substances recommended by the committee for scheduling,
             1655      rescheduling, listing, or deletion from the schedules or list by the Legislature; and
             1656          (b) stating the reasons for the recommendation.
             1657          (3) In advising the Legislature regarding the need to add, delete, relist, or reschedule a
             1658      substance, the committee shall consider:
             1659          (a) the actual or probable abuse of the substance, including:
             1660          (i) the history and current pattern of abuse both in Utah and in other states;
             1661          (ii) the scope, duration, and significance of abuse;
             1662          (iii) the degree of actual or probable detriment to public health which may result from
             1663      abuse of the substance; and
             1664          (iv) the probable physical and social impact of widespread abuse of the substance;
             1665          (b) the biomedical hazard of the substance, including:
             1666          (i) its pharmacology, including the effects and modifiers of the effects of the substance;
             1667          (ii) its toxicology, acute and chronic toxicity, interaction with other substances,
             1668      whether controlled or not, and the degree to which it may cause psychological or physiological
             1669      dependence; and
             1670          (iii) the risk to public health and the particular susceptibility of segments of the


             1671      population;
             1672          (c) whether the substance is an immediate precursor, as defined in Section 58-37-2 , of
             1673      a substance that is currently a controlled substance;
             1674          (d) the current state of scientific knowledge regarding the substance, including whether
             1675      there is any acceptable means to safely use the substance under medical supervision;
             1676          (e) the relationship between the use of the substance and criminal activity, including
             1677      whether:
             1678          (i) persons engaged in illicit trafficking of the substance are also engaged in other
             1679      criminal activity;
             1680          (ii) the nature and relative profitability of manufacturing or delivering the substance
             1681      encourages illicit trafficking in the substance;
             1682          (iii) the commission of other crimes is one of the recognized effects of abuse of the
             1683      substance; and
             1684          (iv) addiction to the substance relates to the commission of crimes to facilitate the
             1685      continued use of the substance;
             1686          (f) whether the substance has been scheduled by other states; and
             1687          (g) whether the substance has any accepted medical use in treatment in the United
             1688      States.
             1689          (4) The committee's duties under this chapter do not include tobacco products as
             1690      defined in Section 59-14-102 or alcoholic beverages as defined in Section 32A-1-105 .
             1691          Section 10. Section 58-38a-204 is amended to read:
             1692           58-38a-204. Guidelines for scheduling or listing drugs.
             1693          (1) (a) The committee shall recommend placement of a substance in Schedule I if it
             1694      finds:
             1695          (i) that the substance has high potential for abuse; and
             1696          (ii) that an accepted standard has not been established for safe use in treatment for
             1697      medical purposes.
             1698          (b) The committee may recommend placement of a substance in Schedule I under
             1699      Section 58-37-4 if it finds that the substance is classified as a controlled substance in Schedule
             1700      I under federal law.
             1701          (2) (a) The committee shall recommend placement of a substance in Schedule II if it


             1702      finds that:
             1703          (i) the substance has high potential for abuse;
             1704          (ii) the substance has a currently accepted medical use in treatment in the United
             1705      States, or a currently accepted medical use subject to severe restrictions; and
             1706          (iii) the abuse of the substance may lead to severe psychological or physiological
             1707      dependence.
             1708          (b) The committee may recommend placement of a substance in Schedule II if it finds
             1709      that the substance is classified as a controlled substance in Schedule II under federal law.
             1710          (3) (a) The committee shall recommend placement of a substance in Schedule III if it
             1711      finds that:
             1712          (i) the substance has a potential for abuse that is less than the potential for substances
             1713      listed in Schedules I and II;
             1714          (ii) the substance has a currently accepted medical use in treatment in the United
             1715      States; and
             1716          (iii) abuse of the substance may lead to moderate or low physiological dependence or
             1717      high psychological dependence.
             1718          (b) The committee may recommend placement of a substance in Schedule III if it finds
             1719      that the substance is classified as a controlled substance in Schedule III under federal law.
             1720          (4) (a) The committee shall recommend placement of a substance in Schedule IV if it
             1721      finds that:
             1722          (i) the substance has a low potential for abuse relative to substances in Schedule III;
             1723          (ii) the substance has currently accepted medical use in treatment in the United States;
             1724      and
             1725          (iii) abuse of the substance may lead to limited physiological dependence or
             1726      psychological dependence relative to the substances in Schedule III.
             1727          (b) The committee may recommend placement of a substance in Schedule IV if it finds
             1728      that the substance is classified as a controlled substance in Schedule IV under federal law.
             1729          (5) (a) The committee shall recommend placement of a substance in Schedule V if it
             1730      finds that:
             1731          (i) the substance has low potential for abuse relative to the controlled substances listed
             1732      in Schedule IV;


             1733          (ii) the substance has currently accepted medical use in treatment in the United States;
             1734      and
             1735          (iii) the substance has limited physiological dependence or psychological dependence
             1736      liability relative to the controlled substances listed in Schedule IV.
             1737          (b) The committee may recommend placement of a substance in Schedule V under this
             1738      chapter if it finds that the substance is classified as a controlled substance in Schedule V under
             1739      federal law.
             1740          (6) The committee may recommend placement of a substance on a controlled substance
             1741      list if it finds that the substance has a potential for abuse and that an accepted standard has not
             1742      been established for safe use in treatment for medical purposes.
             1743          Section 11. Effective date.
             1744          If approved by two-thirds of all the members elected to each house, this bill takes effect
             1745      upon approval by the governor, or the day following the constitutional time limit of Utah
             1746      Constitution Article VII, Section 8, without the governor's signature, or in the case of a veto,
             1747      the date of veto override, except that the amendments to Section 58-37-2 (Effective 07/01/11)
             1748      take effect on July 1, 2011.




Legislative Review Note
    as of 11-18-10 10:26 AM


Office of Legislative Research and General Counsel


[Bill Documents][Bills Directory]